Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
I'm PortAI, I can summarize articles.
Oppenheimer analyst Matthew Biegler has maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL) with a price target of $9.00, while the stock closed at $1.32. The overall analyst consensus for Zentalis is a Moderate Buy, with an average price target of $10.00. Biegler has a -4.2% average return and a 38.97% success rate on his stock recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments